Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.38 |
| ▸ | GALR2 | O43603 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7934246 | 0.88 | PDE10A (0.50) | PDE10ALMNATP53MAPT | |
| SCHEMBL7937147 | 0.88 | PDE10A (0.50) | PDE10ALMNATP53MAPT | |
| SCHEMBL7934257 | 0.85 | PDE10A (0.50) | PDE10AMCHR1GALR2 | |
| SCHEMBL7936495 | 0.84 | PDE10A (0.64) | PDE10AMAPT | |
| SCHEMBL12574927 | 0.84 | PDE10A (0.64) | PDE10AMAPT | |
| SCHEMBL7937697 | 0.84 | PDE10A (0.52) | PDE10ATP53MAPT | |
| SCHEMBL7937698 | 0.84 | PDE10A (0.52) | PDE10ATP53MAPT | |
| SCHEMBL7942725 | 0.83 | PDE10A (0.61) | PDE10ALMNATP53MAPT | |
| SCHEMBL7937161 | 0.82 | PDE10A (0.51) | PDE10AMAPT | |
| SCHEMBL7936493 | 0.81 | PDE10A (0.49) | PDE10AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| WO-2010027097-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | PDE10A 1/4885MCHR1 4319/4885GALR2 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.